Ocular Therapeutix (OCUL) Successfully Appeals Patent Case Against Mati Therapeutics, Inc
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Ocular Therapeutix (OCUL) PT Raised to $30 at JMP Securities
November 9, 2021 6:26 AM ESTJMP Securities analyst Jonathan Wolleben raised the price target on Ocular Therapeutix (NASDAQ: OCUL) to $30.00 (from $27.00) while maintaining a Market Outperform rating.... More
Ocular Therapeutix (OCUL) Tops Q3 EPS by 3c
November 8, 2021 4:34 PM ESTOcular Therapeutix (NASDAQ: OCUL) reported Q3 EPS of ($0.23), $0.03 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $12.15 million versus the consensus estimate of $12.45 million.
For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.
... MoreOcular Therapeutix (OCUL) Announces Update from Centers for Medicare and Medicaid Services for Reimbursement of DEXTENZA
November 5, 2021 9:01 AM EDTOcular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that the Centers for Medicare and Medicaid Services (CMS) released its final rules for the Outpatient Prospective Payment System (OPPS) and Medicare Physician Fee Schedule (MPFS) for 2022.
The OPPS final rule confirms that DEXTENZA will continue to be... More
